Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data

Кобалава, Ж. Д.; Медовщиков, В. В.; Ешниязов, Н. Б.

doi:10.15829/1560-4071-2020-3870

Cited by 6 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Кроме того, подтверждена эффективность иНГЛТ2 в сочетании с тройной нейрогуморальной блокадой у пациентов с ХСНнФВ ЛЖ, в т.ч. без сопутствующего сахарного диабета 2 типа [6], у пациентов с ХСН и сопутствующей хронической болезнью почек, а также получены данные об улучшении качества жизни и клинического состояния при добавлении дапаглифлозина к стандартной терапии ХСНнФВ ЛЖ [7].…”

Section: ключевые моменты Key Messagesunclassified

Twenty-four-year-old patient with heart failure after myocarditis. Results of quadruple therapy: a case report

et al. 2023

View full text Add to dashboard Cite

Introduction. The data of epidemiological studies indicate maintaining high prevalence of heart failure (HF) and an unfavorable prognosis for such patients, which creates the need to change the treatment approach. A feature of the case presented is the young age of the patient and a significant effect that was achieved with quadruple therapy for HF with reduced ejection fraction (EF) after myocarditis.Short description. A three-year follow-up of a patient with HFrEF was carried out. In 2019, at the age of 21, the patient had acute myocarditis, diagnosed according to magnetic resonance imaging. The outcome was postmyocarditis cardiosclerosis, complicated by HFrEF. She had two episodes of HF decompensation, followed by hospitalizations in a cardiology hospital. During the treatment, a quadruple therapy was initiated (angiotensin receptor-neprilysin inhibitor, beta-blocker, mineralocorticoid receptor antagonist, sodium-glucose cotransporter 2 inhibitor), against which a significant improve was noted in the form of decrease in congestion symptoms, natriuretic peptide level from 1956 to 501,4 pg/ml, an increase in LVEF from 33% to 39%. The patient is currently on the waiting list for a donor heart transplant.Conclusion. The case report focuses on the complexity of not only the timely diagnosis of myocarditis, but also the treatment of its consequences. The appointment of quadruple therapy for a patient with HF after myocarditis has improved the patient’s clinical condition before heart transplantation. However, this approach needs to be confirmed in a larger number of patients.

show abstract

Section: ключевые моменты Key Messagesunclassified

Twenty-four-year-old patient with heart failure after myocarditis. Results of quadruple therapy: a case report

et al. 2023

View full text Add to dashboard Cite

show abstract

Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy

Avagimyan,

Sheibani,

Pogosova

et al. 2023

International Journal of Cardiology

View full text Add to dashboard Cite

Chronic kidney disease in patients with type 2 diabetes: new targets of medicine action

et al. 2022

View full text Add to dashboard Cite

Diabetes mellitus type 2 (DM2) is socially important disease, becoming non-infectious epidemic due to increasing prevalence. Chronic kidney disease (CKD) is one of the most common diabetic complications. Kidney injury signs and/or estimated glomerular filtration rate (eGFR) decrease are seen in 40-50% of patients with DM2. Three groups of factors are considered to be the basis of CKD development and progression in DM2: metabolic, hemodynamic, inflammation and fibrosis. Existing drugs that are used in patients with CKD and DM2 first of all target hemodynamic and metabolic disturbances, but their action against inflammation and fibrosis is indirect. Hyperactivation of mineralocorticoid receptors (MR) is considered as one of the main trigger factors of end-organ damage in patients with DM2 due to inflammation and fibrosis. Development of selective nonsteroidal MR antagonists (MRA) as a new class of medications is directed to demonstrate positive effects from blocking this pathophysiological pathway of CKD development and overcome the steroidal MRAs’ shortcomings. Hence pathophysiological hyperactivation of MR with subsequent inflammation and fibrosis in patients with CKD in DM2 is considered a promising therapeutic target for the new drugs with cardionephroprotective effect.

show abstract

Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data

Cited by 6 publications

References 34 publications

Twenty-four-year-old patient with heart failure after myocarditis. Results of quadruple therapy: a case report

Twenty-four-year-old patient with heart failure after myocarditis. Results of quadruple therapy: a case report

Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy

Chronic kidney disease in patients with type 2 diabetes: new targets of medicine action

Contact Info

Product

Resources

About